

Adjuvante Therapie und Rezidivrisiko des Nierenzellkarzinoms

Nils Kröger, Martin Burchardt

Literatur

1. Robert Koch Institut. Zentrum für Krebsregisterdaten im Robert Koch-Institut: Datenbankabfrage mit Schätzung der Inzidenz, Prävalenz und des Überlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten. 2021
2. Ljungberg B et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol* 2022
3. Chamie K et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. *JAMA Oncol* 2017; 3: 913–20
4. Kroeger N et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. *Eur Urol* 2014; 65: 1086–92
5. Haas NB et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet* 2016; 387(10032): 2008–16
6. Motzer RJ et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. *Eur Urol* 2021; 79: 334–8
7. Quinn DI et al. ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups. *ESMO Open* 2021; 6(3): 100105
8. Motzer RJ et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. *Eur Urol* 2018; 73: 62–8
9. Ravaud A et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. *N Engl J Med* 2016; 375: 2246–54
10. Choueiri TK et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. *Journal of Clinical Oncology* 2022; 40(6_suppl): 290
11. Klatte T et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. *Cancer Epidemiol Biomarkers Prev* 2009; 18: 894–900
12. Rini B et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. *Lancet Oncol* 2015; 16: 676–85
13. Rini BI et al. Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. *Clin Cancer Res* 2018; 24: 4407–15
14. Kroeger N et al. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. *Eur J Cancer* 2022; 168: 68–76

15. Kroeger N et al. Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. *J Urol* 2012; 187: 418–23
16. Kroeger N et al. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. *Cancer* 2013; 119: 1547–54
17. Bedke J et al. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. *BJU Int* 2018; 121: 84–92
18. Kattan MW et al. A postoperative prognostic nomogram for renal cell carcinoma. *J Urol* 2001; 166: 63–7
19. Frank I et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. *J Urol* 2003; 170(6 Pt 1): 2225–32
20. Sorbellini M et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. *J Urol* 2005; 173: 48–51
21. Lam JS et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. *J Urol* 2005; 174: 466-72; discussion 72; quiz 801